Intended for licensed healthcare professionals located in the United Kingdom only.

Efficacy

shared.diamonds shared.diamonds

The efficacy of PEMAZYRE® (pemigatinib) was investigated in the FIGHT–202 clinical study (N=108)1

Histogram and magnifying glass

FIGHT–202 was a multicentre, open-label, single-arm study to evaluate the efficacy and safety of PEMAZYRE in previously treated patients with locally advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA).1

The efficacy population consisted of 108 patients (105 patients with intrahepatic disease) whose disease had progressed after at least 1 prior therapy and who had fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement, as determined by the test performed at a central laboratory.1

Patients received PEMAZYRE in 21-day cycles consisting of 13.5 mg once-daily oral dosing for 14 days, followed by 7 days off therapy. PEMAZYRE was administered until disease progression or unacceptable toxicity.1

The major efficacy outcome measures were objective response rate (ORR) and duration of response (DOR), as determined by an independent review committee according to RECIST v1.1.1

Efficacy results1-3

ORR1
(primary endpoint)

37

%

n=40/108

(95% confidence interval [CI]:
27.94–46.86%)1
Complete response = 3.7% (n=4)1
Partial response = 33.3% (n=36)1

Disease control rate (DCR)
= 82.4%
(n=89; 95% CI: 73.9–89.1%)2

Median DOR1
 

8.1

MONTHS

(95% CI: 5.65–13.14 months)a1

Patients with response
maintained for:2


  • ≥6 months, 57.7% (n=23)
  • ≥9 months, 37.5% (n=15)
  • ≥12 months, 25.0% (n=10)

Median time to response1
 

2.7

MONTHS

(range, 0.7-6.9 months)1

a95% CI was calculated using the Brookmeyer and Crowley method.1

Learn more about the baseline demographics

Best percentage change from baseline in target lesion size for individual patients with FGFR2 fusions or rearrangements3

Histogram showing best percentage change from baseline in target lesion size

Tumour response was assessed by independent review. Coloured bars indicate confirmed responses assessed by RECIST v1.1.
Dotted lines indicate the cutoff for partial response (–30%) and progressive disease (+20%).
*Patient had a decrease in target lesion size but was not evaluable for response using RECIST.
Figure reprinted from Abou-Alfa GK, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Lancet Oncol. 2020;21:671–84. Copyright © 2020 with permission from Elsevier Ltd. All rights reserved.

References:

1. PEMAZYRE® (pemigatinib). Summary of Product Characteristics. 2021 (data cutoff: April 2020).
2. Incyte Data on File.
3. Abou-Alfa GK, et al. Lancet Oncol. 2020;21:671–84 (data cutoff: March 2019).

Learn more about PEMAZYRE® (pemigatinib):

Targeted medicine

Discover about FGFR2 fusions in patients with CCA

Targeted medicine FGFR2 fusion testing
DNA helix

Understand the mechanism of action of PEMAZYRE

DNA helix About PEMAZYRE
Shield and tick

Review the safety data of PEMAZYRE

Shield and tick Safety
Clock and pill

Understand the dosing and administration schedule for PEMAZYRE

Clock and pill Dosing and administration
Incyteful Platform

Incyteful for you

An Incyte platform that offers medical education relevant to your daily practice. Easy to access, personalised content that fits with your schedule.

Incyteful is your one-stop resource for updates about the disease areas and Incyte's approved products that you care about.

Coming soon

PEMAZYRE self-directed learning

A self-directed learning material on PEMAZYRE is available to complete in your own time. With the PEMAZYRE learning module, you can learn about the unmet needs in CCA, discuss the need for molecular profiling for early patient identification and learn more about PEMAZYRE.

Learn about PEMAZYRE

PEMAZYRE eDetail